<DOC>
	<DOCNO>NCT00729326</DOCNO>
	<brief_summary>This study design compare short-term effect mechanisms action exenatide sitagliptin either add oral agent ( metformin thiazolidinedione [ TZD ] ) adult patient type 2 diabetes mellitus ( T2DM ) inadequate glycemic control .</brief_summary>
	<brief_title>Comparison Effect Exenatide Versus Sitagliptin 24-hour Average Glucose Patients With Type 2 Diabetes Metformin Thiazolidinedione</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Have type 2 diabetes Has HbA1c 7.0 % 11.0 % , within 4 week prior Visit 1 . Have fast glucose concentration &lt; 280 mg/dL Visit 1 Have treat stable dose immediate extend release metformin least 60 day prior screen OR TZD ( rosiglitazone pioglitazone ) least 120 day prior screen . Are 18 70 year age , inclusive . Have body mass index ≥25 kg/m2 ≤45 kg/m2 . Have history stable body weight ( vary &gt; 10 % least 3 month prior screen ) . Can swallow oral study drug capsule , without split crush . Female patient childbearing potential ( surgically sterilize menarche 1 year postmenopause ) meet follow criterion : Are breastfeed . Test positive pregnancy time screen . Intend become pregnant study . Have practice reliable method birth control ( example , use oral contraceptive Norplant® ; diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ; intrauterine device ; partner vasectomy ; abstinence ) 3 month prior screen . Treated following medication : Insulin , exenatide , pramlintide , sulfonylureas meglitinides within 3 month screen Alphaglucosidase inhibitor within 2 month screen . Drugs directly affect gastrointestinal motility , include , limited metoclopramide , cisapride , chronic macrolide antibiotic . Use drug weight loss ( example , prescription drug orlistat , sibutramine , phentermine , similar overthecounter medication ) within 3 month prior Visit 1 . Systemic corticosteroid oral , intravenous , intramuscular route within 2 month screen . Have history renal transplantation currently receive renal dialysis . Have obvious clinical sign symptom liver disease acute chronic hepatitis . Have know active proliferative retinopathy macular edema expect need treatment focal photocoagulation within 3 month . Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have organ transplantation . Have receive GLP1 analog exenatide DPP4 inhibitor within previous 3 month . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>metformin</keyword>
	<keyword>thiazolidinedione</keyword>
</DOC>